Neil E Martin

List of Publications by Year
in descending order

143 papers	4,464 citations	109137 35 h-index	114278 63 g-index
143 all docs	143 docs citations	143 times ranked	7681 citing authors

#	Article	IF	Citations
1	Marital Status and Survival in Patients With Cancer. Journal of Clinical Oncology, 2013, 31, 3869-3876.	0.8	789
2	The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1497-1509.	1.1	268
3	Lack of reduction in racial disparities in cancerâ€specific mortality over a 20â€year period. Cancer, 2014, 120, 1532-1539.	2.0	204
4	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	0.9	190
5	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396.	0.8	140
6	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	0.8	112
7	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. Cancer Research, 2010, 70, 3136-3139.	0.4	110
8	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.2	109
9	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nature Communications, 2017, 8, 420.	5.8	91
10	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	0.5	86
11	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	0.8	81
12	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. Journal of the National Cancer Institute, 2013, 105, 1881-1890.	3.0	80
13	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	0.9	79
14	A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 5447-5454.	3.2	73
15	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
16	Clinical and Genomic Characterization of Lowâ€“Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	0.9	72
17	Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 756-764.	0.4	71
18	SPINK1 Protein Expression and Prostate Cancer Progression. Clinical Cancer Research, 2014, 20, 4904-4911.	3.2	71

#	Article	IF	Citations
19	Outcomes in stage I testicular seminoma: A populationâ€based study of 9193 patients. Cancer, 2013, 119, 2771-2777.	2.0	69
20	Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1411-1416.	0.4	67
21	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	1.3	66
22	The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer and Prostatic Diseases, 2014, 17, 273-279.	2.0	57
23	Association Between Treatment at a High-Volume Facility and Improved Survival forÂRadiation-Treated Men With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 683-690.	0.4	57
24	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	0.8	53
25	Low-Dose Involved-Field Radiation in the Treatment of Non-Hodgkin Lymphoma: Predictors of Response and Treatment Failure. International Journal of Radiation Oncology Biology Physics, 2013, 86, 121-127.	0.4	49
26	Prognostic Determinants in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 429-437.	1.0	48
27	Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-Up Study. Journal of Clinical Oncology, 2014, 32, 3033-3038.	0.8	46
28	Racial Disparities in Prostate Cancerâ€“Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	0.9	46
29	Progress and controversies: Radiation therapy for prostate cancer. Ca-A Cancer Journal for Clinicians, 2014, 64, 389-407.	157.7	44
30	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3214-3222.	3.2	44
31	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1984-1993.	1.1	41
32	Definition and Validation of â€œFavorable High-Risk Prostate Cancerâ€: Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.4	40
33	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. European Urology Focus, 2019, 5, 69-76.	1.6	40
34	Implementing patient-reported outcome surveys as part of routine care: lessons from an academic radiation oncology department. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 964-968.	2.2	39
35	Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy, 2014, 13, 442-449.	0.2	38
36	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy, 2016, 15, 274-282.	0.2	37

#	Article	IF	Citations
37	Use and early mortality outcomes of active surveillance in patients with intermediateâ€risk prostate cancer. Cancer, 2019, 125, 3164-3171.	2.0	35
38	Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer, 2011, 117, 406-413.	2.0	28
39	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	2.0	27
40	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer, 2016, 122, 1505-1512.	2.0	27
41	Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians' Health Study. International Journal of Radiation Oncology Biology Physics, 2012, 83, 28-32.	0.4	26
42	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer & Metabolism, 2016, 4, 22.	2.4	26
43	Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 137-43.	0.8	26
44	Stage at presentation and survival outcomes of patients with Gleason 8â€“10 prostate cancer and low prostate-specific antigen. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e19-119.e26.	0.8	25
45	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. Journal of Contemporary Brachytherapy, 2016, 1, 1-6.	0.4	23
46	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 374-381.	1.2	22
47	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	1.3	22
48	Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality. Journal of Urology, 2012, 187, 2068-2073.	0.2	21
49	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	0.5	21
50	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21
51	Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer, 2018, 124, 1141-1149.	2.0	21
52	A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clinical Cancer Research, 2013, 19, 1612-1619.	3.2	20
53	Receipt of definitive therapy in elderly patients with unfavorableâ€risk prostate cancer. Cancer, 2017, 123, 4832-4840.	2.0	20
54	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. European Urology, 2018, 73, 262-270.	0.9	20

#	Article	IF	Citations
55	Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus Paper. Practical Radiation Oncology, 2019, 9, 395-401.	1.1	20
56	Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less. Clinical Genitourinary Cancer, 2015, 13, e1-e6.	0.9	19
57	Interstitial photodynamic therapy for prostate cancer: a developing modality. Photodiagnosis and Photodynamic Therapy, 2004, 1, 123-136.	1.3	18
58	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9â€“10 Prostate Cancer. European Urology, 2019, 75, 35-41.	0.9	18
59	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
60	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	0.8	17
61	Incidence and determinants of 1-month mortality after cancer-directed surgery. Annals of Oncology, 2015, 26, 399-406.	0.6	16
62	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with â‰¥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	0.5	16
63	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Molecular Cancer Research, 2015, 13, 1431-1440.	1.5	15
64	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
65	New developments in prostate cancer biomarkers. Current Opinion in Oncology, 2016, 28, 248-252.	1.1	14
66	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 953-959.	0.6	14
67	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clinical Genitourinary Cancer, 2018, 16, 226-234.	0.9	14
68	Pharmacogenomics of <scp>cisplatinâ€induced</scp> neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Medicine, 2022, 11, 2801-2816.	1.3	14
69	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.2	13
70	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	0.6	13
71	Risk of All-Cause and Prostate Cancerâ€“Specific Mortality After Brachytherapy in Men With Small Prostate Size. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1318-1322.	0.4	11
72	Impact of a clinical pathway tool on appropriate palliative radiation therapy for bone metastases. Practical Radiation Oncology, 2018, 8, 266-274.	1.1	11

#	Article	IF	Citations
73	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	2.3	10
74	Radiation Oncology Health Information Technology: Is It Working For or Against Us?. International Journal of Radiation Oncology Biology Physics, 2017, 98, 259-262.	0.4	10
75	Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer. Journal of Contemporary Brachytherapy, 2016, 4, 319-325.	0.4	9
76	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.4	9
77	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clinical Genitourinary Cancer, 2020, 19, 246-254.e5.	0.9	9
78	Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: Implications for the use of newer isotopes. Brachytherapy, 2014, 13, 152-156.	0.2	8
79	Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate, 2015, 75, 1926-1933.	1.2	8
80	GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clinical Genitourinary Cancer, 2015, 13, 370-377.e1.	0.9	8
81	Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas. Leukemia and Lymphoma, 2009, 50, 1765-1772.	0.6	7
82	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	0.9	7
83	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Advances in Radiation Oncology, 2017, 2, 140-147.	0.6	7
84	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiotherapy and Oncology, 2021, 161, 241-250.	0.3	7
85	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	0.8	6
86	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 904-911.	0.4	6
87	Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU International, 2012, 110, 1252-1256.	1.3	5
88	Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy, 2013, 12, 415-421.	0.2	5
89	Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators. Prostate Cancer, 2014, 2014, 1-6.	0.4	5
90	Improving What Matters. European Urology, 2015, 68, 384-385.	0.9	5

#	Article	IF	Citations
91	Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy. Clinical Genitourinary Cancer, 2017, 15, 237-241.	0.9	5
92	Treating the SARSâ€CoVâ€2â€“positive patient with cancer: A proposal for a pragmatic and transparent ethical process. Cancer, 2020, 126, 3896-3899.	2.0	5
93	How Can I Help Myself? A Critical Review of Modifiable Behaviors, Medications, and Complementary Alternative Medicine for Men Receiving Radiotherapy for Prostate Cancer. Seminars in Radiation Oncology, 2013, 23, 173-181.	1.0	4
94	Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer, 2014, 120, 824-832.	2.0	4
95	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy, 2015, 14, 511-516.	0.2	4
96	Reply to Steven MacLennan, Paula R. Williamson, and Thomas B. Lam's Letter to the Editor re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460â€“7. European Urology, 2015, 68, e125-e126.	0.9	3
97	Analysis of After-Hours Patient Telephone Calls in Two Academic Radiation Oncology Departments: An Opportunity for Improvement in Patient Safety and Quality of Care. Journal of Oncology Practice, 2016, 12, e487-e494.	2.5	3
98	The influence of serial prostateâ€specific antigen (PSA) screening on the PSA velocity at diagnosis. Cancer, 2008, 113, 717-722.	2.0	2
99	Now Youâ€™re Speaking My Language: Getting Patient-reported Outcomes to Talk to One Another. European Urology, 2019, 75, 731-732.	0.9	2
100	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e9-735.e15.	0.8	2
101	A Virtual Prostate Cancer Clinic for Prostate-Specific Antigen Monitoring: Improving Well Visits and Freeing Up Time for Acute Care. NEJM Catalyst, 2021, 2, .	0.4	2
102	Standardizing patient-centered outcomes measurement in prostate cancer: An international, cross-disciplinary effort.. Journal of Clinical Oncology, 2014, 32, 271-271.	0.8	2
103	Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Practical Radiation Oncology, 2012, 2, 172-178.	1.1	1
104	Doing It Right: How, Not Whether, To Perform Prostate-specific Antigen Screening. European Urology, 2015, 68, 361-362.	0.9	1
105	Reply to Daniela Wittmann, Ted A. Skolarusâ€™ Letter to the Editor re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2014;67:460â€“7. European Urology, 2016, 69, e127.	0.9	1
106	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262â€“70. European Urology, 2018, 73, e100-e101.	0.9	1
107	Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate.. Journal of Clinical Oncology, 2013, 31, 161-161.	0.8	1
108	Genomic features of primary and recurrent anal squamous cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 556-556.	0.8	1

#	Article	IF	Citations
109	Development and implementation of a clinical pathway for radiation of bone metastases on a palliative radiation oncology service.. Journal of Clinical Oncology, 2016, 34, 170-170.	0.8	1
110	The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients.. Journal of Clinical Oncology, 2017, 35, 19-19.	0.8	1
111	Impact of a clinical pathway tool on appropriate palliative radiation therapy for bone metastases.. Journal of Clinical Oncology, 2017, 35, 97-97.	0.8	1
112	Successes with and barriers to patient-reported outcome deployment at a comprehensive cancer center.. Journal of Clinical Oncology, 2018, 36, 292-292.	0.8	1
113	Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer.. Journal of Clinical Oncology, 2020, 38, 101-101.	0.8	1
114	Defining a Standard Set of Patient-Centered Outcomes for Men With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S598-S599.	0.4	0
115	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermannsâ€™ Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262â€“70.. European Urology, 2018, 73, e96-e97.	0.9	0
116	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8â€“10 prostate cancer. Brachytherapy, 2021, 20, 1-9.	0.2	0
117	Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. Journal of Clinical Oncology, 2021, 39, 121-121.	0.8	0
118	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.. Journal of Clinical Oncology, 2021, 39, 12004-12004.	0.8	0
119	Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.. Journal of Clinical Oncology, 2013, 31, 2-2.	0.8	0
120	Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes.. Journal of Clinical Oncology, 2013, 31, 232-232.	0.8	0
121	Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy.. Journal of Clinical Oncology, 2013, 31, 82-82.	0.8	0
122	Identifying men at greatest risk of weight gain from androgen deprivation therapy.. Journal of Clinical Oncology, 2014, 32, 80-80.	0.8	0
123	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. Journal of Clinical Oncology, 2014, 32, 5091-5091.	0.8	0
124	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2015, 33, 32-32.	0.8	0
125	Stage at presentation and survival outcomes of patients with Gleason 8 to 10 prostate cancer and low PSA.. Journal of Clinical Oncology, 2015, 33, 21-21.	0.8	0
126	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. Journal of Clinical Oncology, 2015, 33, 34-34.	0.8	0

#	Article	IF	Citations
127	Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. Journal of Clinical Oncology, 2016, 34, 494-494.	0.8	0
128	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 54-54.	0.8	0
129	Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 52-52.	0.8	0
130	Implementing patient-reported outcome surveys as part of routine care: Lessons from an academic radiation oncology department.. Journal of Clinical Oncology, 2016, 34, 97-97.	0.8	0
131	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 50-50.	0.8	0
132	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. Journal of Clinical Oncology, 2017, 35, 18-18.	0.8	0
133	Patient-reported outcomes for performance measurement: Multi-institution challenges.. Journal of Clinical Oncology, 2017, 35, 211-211.	0.8	0
134	Practice patterns and outcomes among patients with N0M0 prostate cancer and a very high prostate-specific antigen.. Journal of Clinical Oncology, 2018, 36, 48-48.	0.8	0
135	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 78-78.	0.8	0
136	Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.. Journal of Clinical Oncology, 2018, 36, 23-23.	0.8	0
137	Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.. Journal of Clinical Oncology, 2018, 36, 59-59.	0.8	0
138	Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.. Journal of Clinical Oncology, 2018, 36, 10058-10058.	0.8	0
139	Implementing radiation oncology pathways at Dana-Farber Cancer Institute/Brigham and Womenâ€™s Hospital.. Journal of Clinical Oncology, 2018, 36, 301-301.	0.8	0
140	Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).. Journal of Clinical Oncology, 2019, 37, e16058-e16058.	0.8	0
141	Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 941-948.	2.3	0
142	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. Journal of Clinical Oncology, 2020, 38, 280-280.	0.8	0
143	Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS).. Journal of Clinical Oncology, 2022, 40, 12080-12080.	0.8	0